Condition
18F-FDG
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (2)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04588064Not ApplicableCompleted
18F-FDG and 68Ga-FAPI PET/CT in Lung Adenocarcinoma
NCT06190574CompletedPrimary
Diagnostic Efficacy and Prognostic Value of 18F-FDG PET/CT (MR) in Pediatric Solid Blastoma
NCT05884463Not ApplicableCompleted
18F-FAPI PET Imaging in Pancreatic Adenocarcinoma
NCT03741231Completed
18FDG-PET in Patients With Melanoma or NSCLC Treated With Immunotherapy
Showing all 4 trials